GB2568929A — Use of cannabinoids in the treatment of epilepsy

USPTO Abstract

Disclosed is the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking an immunosuppressant drug characterised in that the blood levels of the immunosuppressant drug is monitored to ensure blood levels of the immunosuppressive compound do not become toxic. Preferably, the condition to be treated is one of; Lennox-Gastaut syndrome, myoclonic absence epilepsy, tuberous sclerosis complex, Dravet syndrome, Doose syndrome, Jeavons syndrome, CDKL5, neuronal ceroid lipofuscinoses (NCL). Preferably, the immunosuppressant drug is tacrolimus. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%.